Bicycle Therapeutics (BCYC) vs Cypherpunk Technologies (CYPH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Cypherpunk Technologies (CYPH) has outperformed Bicycle Therapeutics (BCYC) over the past year, losing 38.2% versus a loss of 54.1%. Over five years, CYPH leads with a -94.4% price change compared with -94.7% for BCYC. Cypherpunk Technologies is the larger company by market cap ($210.1 million vs $203.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCYC | CYPH |
|---|---|---|
| Share price | $2.90 | $1.41 |
| Market cap | $203.27M | $210.15M |
| 1-day change | -4.92% | -18.02% |
| YTD return | -59.04% | +21.55% |
| 1-year return | -54.11% | -38.16% |
| 5-year return | -94.69% | -94.45% |
| P/E ratio (TTM) | — | 0.67 |
| EPS (TTM) | $-2.03 | $2.09 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $72.59M | — |
| Revenue growth (YoY) | +105.77% | — |
| Net income (latest FY) | $-218.96M | $4.82M |
| Operating margin | -340.38% | — |
| Net margin | -301.66% | — |
| 52-week high | $7.83 | $4.19 |
| 52-week low | $2.85 | $0.491 |
| Distance from 52-week high | -62.96% | -66.35% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +216.21% | +254.61% |
| Average volume | 444.72K | 15.42M |
| Shares outstanding | 50.66M | 149.04M |
| Employees | 288 | 6 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CYPH has outperformed BCYC by 16.0 percentage points over the past year.
About Bicycle Therapeutics
BCYC stock →Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing.
Health Care · Biotechnology: Pharmaceutical Preparations · 288 employees
About Cypherpunk Technologies
CYPH stock →Cypherpunk Technologies Inc., a privacy technology company, implements a digital asset strategy anchored by Zcash in the United States. The company is involved in identifying, developing, investing in, acquiring, and building privacy-enhancing technologies; and accumulating digital assets, such as ZCash.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
BCYC vs CYPH FAQ
Which is bigger, Bicycle Therapeutics or Cypherpunk Technologies?
Cypherpunk Technologies (CYPH) is larger, with a market capitalization of $210.15M compared with $203.27M for Bicycle Therapeutics (BCYC).
Which stock has performed better over the past year, BCYC or CYPH?
CYPH returned -38.16% over the past 12 months, compared with -54.11% for BCYC (price return, excluding dividends). Past performance does not predict future results.
Are Bicycle Therapeutics and Cypherpunk Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.